Key result
Sanger sequencing identifies 11 potentially pathogenic cardiomyopathy variants, clustering predominantly in MYH7 exon 23.
Why the study?
Does Sanger sequencing of selected exons identify potentially pathogenic sequence variants in East Slovak patients with hypertrophic cardiomyopathy?
Case-Control (n=48)
No
Does Sanger sequencing of selected exons identify potentially pathogenic sequence variants in East Slovak patients with hypertrophic cardiomyopathy?
Targeted Sanger sequencing reveals a notable burden of potentially pathogenic, including novel, genetic variants in sarcomeric and non-sarcomeric genes among East Slovak patients with hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Highlights regional HCM variants; extends genetic data to East Slovak patients but should not yet change practice.
BACKGROUND: Hypertrophic cardiomyopathy is a heterogeneous myocardial disease. Mutations appearing in several genes might be a potential cause of the disease. The aim of the study was to analyze selected exons of the sarcomeric and non-sarcomeric genes, with the purpose to identify potential candidate genetic variants and to understand etiopathogenetic mechanisms of hypertrophic cardiomyopathy in East Slovak patients. METHODS: This study recruited 23 unrelated patients with hypertrophic cardiomyopathy, namely, 13 men and 10 women (mean age of 58.09±15.82 years) and 25 healthy controls in order to determine the candidate sequence variants, in the selected exons of six cardiomyopathy genes (MYBPC3, MYH7, NEBL, SCN5A, TNNI3, TNNT2), by conventional capillary-based Sanger sequencing method and standard protocols. RESULTS: Molecular genetic results confirmed the presence of 43 sequence variants in the selected exons of six cardiomyopathy genes, 58.14% of detected variants were novel. The majority of detected sequence variants were confirmed within exon 23 of MYH7 gene. Only 11 genetic alterations were predicted to be potentially pathogenic. CONCLUSIONS: In our study, we identified known and novel sequence variants in 23 unrelated patients with hypertrophic cardiomyopathy, but we did not observe any strong mutation hotspot. The results of our study assumed that exon 23 of MYH7 gene can be in potential affinity to hypertrophic cardiomyopathy in our cohort of patients. The sequence variants identified in this study may be further investigated in order to determine their functions in disease pathogenesis and improve management, diagnosis, and treatment in Slovak patients.
No takes yet. Share an insight, caveat, or question.
Zigová et al. (2017) conducted a case-control in Hypertrophic cardiomyopathy (n=48). Presence of sequence variants in 6 cardiomyopathy genes vs. Healthy controls was evaluated on Detection of candidate sequence variants in selected exons of MYBPC3, MYH7, NEBL, SCN5A, TNNI3, and TNNT2 genes. Sanger sequencing identified 43 sequence variants across six genes, with 11 predicted to be potentially pathogenic, predominantly in exon 23 of the MYH7 gene.
Synapse has enriched 10 related papers. Consider them for comparative context: